{
    "id": 25860,
    "fullName": "PIK3CA P447_L455del",
    "impact": "deletion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA P447_L455del results in the deletion of nine amino acids in the C2 PI3K-type domain of the Pik3ca protein from amino acids 447 to 455 (UniProt.org). P447_L455del confers a gain of function to the Pik3ca protein as demonstrated by transformation in culture and activation of the PI3K/Akt/Mtor pathway via increased phosphorylation of Akt, Erk, P70S6K, and P90RSK (PMID: 21266528, PMID: 29284706).",
            "references": [
                {
                    "id": 2211,
                    "pubMedId": 21266528,
                    "title": "A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21266528"
                },
                {
                    "id": 11043,
                    "pubMedId": 29284706,
                    "title": "PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K\u03b1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29284706"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "P447_L455del",
    "createDate": "01/05/2017",
    "updateDate": "03/20/2018",
    "referenceTranscriptCoordinates": {
        "id": 172050,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179210274_179210300del27",
        "cDna": "c.1340_1366del27",
        "protein": "p.P447_L455delPVPHGLEDL",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13279,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with estrogen-receptor positive breast cancer harboring PIK3CA P447_L455del demonstrated an 11 month sustained response to the combination therapy of Femara (letrozole) and Alpelisib (BYL719) (PMID: 29284706).",
            "molecularProfile": {
                "id": 26982,
                "profileName": "PIK3CA P447_L455del"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11043,
                    "pubMedId": 29284706,
                    "title": "PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K\u03b1 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29284706"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9697,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA P447_L455del demonstrated a partial response when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994).",
            "molecularProfile": {
                "id": 26983,
                "profileName": "ESR1 pos PIK3CA P447_L455del"
            },
            "therapy": {
                "id": 1553,
                "therapyName": "Alpelisib + Letrozole",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7484,
                    "pubMedId": 27126994,
                    "title": "A Phase Ib Study of Alpelisib (BYL719), a PI3K\u03b1-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27126994"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26982,
            "profileName": "PIK3CA P447_L455del",
            "profileTreatmentApproaches": [
                {
                    "id": 17490,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA P447_L455del"
                },
                {
                    "id": 17494,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA P447_L455del"
                },
                {
                    "id": 17487,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA P447_L455del"
                },
                {
                    "id": 17492,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA P447_L455del"
                },
                {
                    "id": 17493,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA P447_L455del"
                },
                {
                    "id": 17488,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA P447_L455del"
                },
                {
                    "id": 17489,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA P447_L455del"
                },
                {
                    "id": 17491,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA P447_L455del"
                }
            ]
        },
        {
            "id": 26983,
            "profileName": "ESR1 pos PIK3CA P447_L455del",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 172049,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179210274_179210300del27",
            "cDna": "c.1340_1366del27",
            "protein": "p.P447_L455delPVPHGLEDL",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 172051,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179210274_179210300del27",
            "cDna": "c.1340_1366del27",
            "protein": "p.P447_L455delPVPHGLEDL",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 172050,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179210274_179210300del27",
            "cDna": "c.1340_1366del27",
            "protein": "p.P447_L455delPVPHGLEDL",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}